Celebrating 2000 publications citing Olink

A significant milestone for proteomics research

We have some exciting news to share!  The use of Olink’s Proximity Extension Assay (PEA) technology has now been cited in over 2,000 peer-reviewed scientific publications. This milestone reflects the rapidly growing impact of next-generation proteomics to accelerate innovative research across a broad spectrum of disease areas and biologies.

From the very first PEA publication to 1,000 articles took an impressively short 8 years, but this output has now doubled to over 2,000 in just 2 more years. This acceleration mirrors the rising significance of protein biomarkers in biomedical research and the establishment of Olink as an enabling solution for these types of studies.

An exceptional body of work

Progressing from largely small-scale observational studies in the early days of PEA, scientists have increasingly used Olink technology in larger, more comprehensive studies in which proteomics data plays a key role in gaining real biological insights across a wide range of disciplines. This has been reflected in the proportion of Olink-based articles appearing in higher-rated journals. While around 25% of these papers were published in journals with an impact factor over 5.9 (equating to the top ~5-10% of biological journals) during the first 4 years, this number has jumped to >50% in the last 3 years. This is a testament to the outstanding work performed by Olink’s customers, a growing acceptance of the essential role of proteomics in biomedical research, and the power of PEA to accelerate progress in this field.

A rapidly developing field

The adoption of next-generation proteomics as a key technology across the spectrum of biological research is rapidly advancing and developing this field, This can be seen in some clear trends in the scientific literature citing the use of Olink.

• A central role for proteomics in comprehensive multiomic studies, most notably in combination with genomics data (“proteogenomics”), but also encompassing the entire span of omics approaches.
• Extensive meta-analysis studies combining PEA protein data with large GWAS datasets and using Mendelian Randomization to determine proteins with causal roles in disease.
• A rapidly increasing use of protein biomarker analysis in clinical trial samples, providing valuable insights into drug responses and modes of action.

Protein biomarkers are enhancing genomic discoveries by bridging the genotype-phenotype gap, thereby enabling new clinical tools and accelerating the advancement of precision medicine. Olink is dedicated to advancing meaningful biology and we’re proud to be part of so many studies that span oncology, neurology, immunology, cardiology, and more. Moreover, we are proud to support studies that have a lasting impact and that keep growing our scientific understanding.

An Olink perspective from Dr. Cindy Lawley

Our Senior Director of Population Health, Cindy Lawley Ph.D., took a few moments to reflect on the remarkable body of work published by Olink customers so far.

Empowering the scientific community

We are continuously innovating and working with researchers worldwide, and supporting major initiatives like the UK Biobank Pharma Proteomics Project (UKB-PPP). This unique resource for the wider scientific community has resulted in over 65 publications covering a broad range of disease biology since the dataset was made available in late 2023. Similarly, Olink data published by the independent proteogenomics consortium, SCALLOP, has resulted in over 50 articles related to major disease areas.

We’re excited to keep pushing the boundaries of proteomics research together with you. Thank you for being part of this journey. Let’s continue to make meaningful biology happen!